Adial Pharmaceuticals (ADIL) Price & Analysis

Compare

590 Followers

ADIL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.22 - $1.30

Previous CloseN/A

Volume36.45K

Average Volume (3M)643.90K

Market Cap

$8.70M

Enterprise Value-$2.70M

Total Cash (Recent Filing)$5.91M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Nov 18, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding21,828,215

10 Day Avg. Volume727,818

30 Day Avg. Volume643,902

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)4.62

Price to Sales (P/S)0.00

P/FCF Ratio-2.71

Enterprise Value/Market Cap-0.31

Enterprise Value/Revenue-4.80K

Enterprise Value/Gross Profit4.79K

Enterprise Value/Ebitda0.33

Forecast

1Y Price Target

$1.50

Price Target Upside275.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Innovative TreatmentThe new Phase 3 study will incorporate biomarker-driven patient selection, focusing on a genetically defined subset of AUD patients, positioning AD04 as a potential first-in-class precision medicine for AUD.

Manufacturing CapabilityAdial announced securing US-based manufacturing for AD04 through agreements with Cambrex and Thermo Fisher Scientific to support P3 studies and planned NDA submission for AUD.

Regulatory ApprovalRegulatory clarity from the FDA on the Phase 3 study design resolves the primary uncertainty around the path forward for AD04, allowing the study to be viewed as partially de-risked.

Bears Say

Financial NeedsThe company still needs additional capital or partnership to fund the study, despite having $5.9M in cash reported at the end of 2Q25, which should provide operating capital into 2Q26.

Financial PerformanceAdial reported 2Q25 results with a net loss of ($2.0M) and ended the period with $5.9M in cash on the balance sheet.

Investment RatingAnalyst maintains a Hold rating as further clarity on funding or partnering plans is awaited to advance AD04 into P3 for AUD.

Adial Pharmaceuticals News

CoreWeave initiated, Instacart downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5d ago

FCX

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

Maxim upgraded Adial Pharmaceuticals (ADIL) to Buy from Hold with a $1.50 price target Published first on TheFly...

6d ago

ADIL

Adial announces receipt of final meeting minuts from EOP2 meeting with FDA

Adial Pharmaceuticals (ADIL) announced receipt of the final meeting minutes from its End of Phase 2, EOP2, Meeting...

20d ago

ADIL

Adial Pharmaceuticals Advances AD04 with FDA Support

Adial Pharmaceuticals ( ($ADIL) ) has shared an update. On September 16, 2025, Adial Pharmaceuticals announced receiving final...

20d ago

ADIL

Adial Pharmaceuticals Granted Nasdaq Compliance Extension

An update from Adial Pharmaceuticals ( ($ADIL) ) is now available. On September 2, 2025, Adial Pharmaceuticals received...

1M ago

ADIL

Adial granted a 180 calendar day extension by Nasdaq to regain compliance

Adial Pharmaceuticals (ADIL) announced that it has been granted a 180 calendar day extension from The Nasdaq Stock...

1M ago

ADIL

Adial encouraged by U.S. Senate support for extended AUD trial endpoints

Adial Pharmaceuticals (ADIL) “applauded” recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance...

2M ago

ADIL

Adial Pharmaceuticals expects cash to fund operations into Q2 of 2026

The company reported Q2 results. Cash and cash equivalents were $5.9 million as of June 30, 2025, compared...

2M ago

ADIL

ADIL Upcoming Earnings Report: What to Expect?

Adial Pharma (ADIL) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street analysts...

2M ago

ADIL

Adial Pharmaceuticals completes EOP2 FDA meeting

Adial Pharmaceuticals (ADIL) announced the completion of a successful End of Phase 2 meeting, EOP2M, with the Food...

2M ago

ADIL

Adial Pharmaceuticals Enters New Sales Agreement

An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. On August 1, 2025, Adial Pharmaceuticals entered...

2M ago

ADIL

Adial Pharmaceuticals Approves Share Increase at Annual Meeting

Adial Pharmaceuticals ( ($ADIL) ) has provided an announcement. On August 1, 2025, Adial Pharmaceuticals held its Annual...

2M ago

ADIL

Adial Pharmaceuticals Regains Nasdaq Compliance After Offering

Adial Pharmaceuticals ( ($ADIL) ) just unveiled an update. On May 23, 2025, Adial Pharmaceuticals received a letter...

3M ago

ADIL

Adial regains compliance with Nasdaq’s Equity Listing requirement

Adial Pharmaceuticals (ADIL) announced that it received notice from Nasdaq on July 14, 2025 that the Company has...

3M ago

ADIL

ADIL FAQ

What was Adial Pharmaceuticals Inc’s price range in the past 12 months?

Adial Pharmaceuticals Inc lowest stock price was $0.22 and its highest was $1.30 in the past 12 months.

What is Adial Pharmaceuticals Inc’s market cap?

Adial Pharmaceuticals Inc’s market cap is $8.70M.

When is Adial Pharmaceuticals Inc’s upcoming earnings report date?

Adial Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2025 which is in 43 days.

How were Adial Pharmaceuticals Inc’s earnings last quarter?

Adial Pharmaceuticals Inc released its earnings results on Aug 14, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.22 by $0.04.

Is Adial Pharmaceuticals Inc overvalued?

According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adial Pharmaceuticals Inc pay dividends?

Adial Pharmaceuticals Inc does not currently pay dividends.

What is Adial Pharmaceuticals Inc’s EPS estimate?

Adial Pharmaceuticals Inc’s EPS estimate is -0.14.

How many shares outstanding does Adial Pharmaceuticals Inc have?

Adial Pharmaceuticals Inc has 21,828,215 shares outstanding.

What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?

Adial Pharmaceuticals Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.22. Following the earnings report the stock price went down -2.5%.

Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ADIL

Company Description

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals (ADIL) Earnings & Revenues

Historic Earnings Reports

ADIL Stock 12 Month Forecast

Average Price Target

$1.50

▲(275.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.38,0.46615384615384614,0.5523076923076924,0.6384615384615385,0.7246153846153847,0.8107692307692308,0.896923076923077,0.9830769230769232,1.0692307692307694,1.1553846153846155,1.2415384615384615,1.327692307692308,1.413846153846154,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.38,0.46615384615384614,0.5523076923076924,0.6384615384615385,0.7246153846153847,0.8107692307692308,0.896923076923077,0.9830769230769232,1.0692307692307694,1.1553846153846155,1.2415384615384615,1.327692307692308,1.413846153846154,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.38,0.46615384615384614,0.5523076923076924,0.6384615384615385,0.7246153846153847,0.8107692307692308,0.896923076923077,0.9830769230769232,1.0692307692307694,1.1553846153846155,1.2415384615384615,1.327692307692308,1.413846153846154,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.23,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >